Indiana Myeloma Registry for blood cancer-related diagnoses
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This registry collects information from adults with certain plasma-cell conditions like MGUS, smoldering multiple myeloma, multiple myeloma, plasmacytoma, or primary amyloidosis. It may help researchers learn more about these diseases and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old when you agree to join
- You have been diagnosed with one of these conditions (or a doctor suspects it): MGUS, smoldering multiple myeloma, multiple myeloma, plasmacytoma, or primary amyloidosis
- Your condition fits the kinds of “plasma-cell” diseases the registry is tracking
- You must be able to give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects health information and, if needed, samples from people diagnosed with certain blood disorders related to plasma cells. Sharing your information may help researchers better understand these diseases and improve future care.
This study creates a registry to track patients with plasma cell disorders, which are conditions where abnormal cells build up in the bone marrow. Joining this registry helps researchers learn more about these diseases and improve future care.
This study is a registry that collects information about adults with plasma cell disorders (conditions involving abnormal antibody-producing cells). It may help researchers understand these diseases better and improve future care by tracking patients over time.
This study creates a long-term database of patients with plasma cell disorders (such as multiple myeloma) to improve future care. You would be helping doctors learn more about these conditions by sharing your records over time.
This study collects information from multiple myeloma patients who previously took part in a GMMG therapy study. It helps researchers learn more about the disease and treatments over time.
This study creates a real-world registry (a group database) of people with active, symptomatic multiple myeloma. It helps researchers learn from patients and doctors over time and may support future research and treatment improvements.
Hear when a new Plasma Cell Dyscrasias trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.